Key result
Sacubitril/valsartan attenuates hypoxic cardiomyocyte injury via M2 polarization and lower TLR4/NF-κB signaling.
Why the study?
The exact mechanism by which sacubitril/valsartan exerts its cardioprotective effect in myocardial infarction remains to be explored further.
Sacubitril/valsartan protects cardiomyocytes from hypoxia/reoxygenation injury in vitro by promoting M2 macrophage polarization and inhibiting the TLR4/NF-κB pathway.
Answers are grounded in this paper and cite their sources.
Should not yet change clinical practice; extends preclinical evidence for sacubitril/valsartan in ischemia-reperfusion injury.
BACKGROUND: Cardiomyocyte apoptosis and inflammation are critical mediators in myocardial infarction (MI) progression. Sacubitril/valsartan (Sac/Val) is an angiotensin receptor-neprilysin inhibitor that has demonstrated therapeutic efficacy in MI treatment. Nonetheless, the exact mechanism by which Sac/Val exerts its cardioprotective effect in MI remains to be explored further. METHODS: Human cardiomyocytes (AC16) were pretreated with Sac/Val and exposed to hypoxia-oxygenation (H/R) to mimic MI in vitro. The conditioned medium (CM) of THP-1 macrophages was collected to co-culture with AC16 cells. CCK-8 assays were conducted to evaluate cell viability. A pharmacological inhibitor, TAK242, was utilized to block TLR4 signaling. Lactate dehydrogenase (LDH) release in the culture medium was estimated. Flow cytometry was performed for cell apoptosis analysis and macrophage marker detection. Western blotting was used to detect protein expression. RESULTS: Sac/Val pretreatment restored viability, alleviated apoptosis, and reduced proinflammatory cytokine production in H/R-exposed AC16 cells. Sac/Val hindered THP-1 cell polarization toward M1 phenotypes, while facilitating polarization toward M2 phenotypes, accompanied by TLR4/NF-κB signaling inhibition. Conditioned medium from Sac/Val- or TAK-242-treated THP-1 cells markedly reduced AC16 cell apoptosis and proinflammatory cytokine production under H/R exposure. CONCLUSION: Sac/Val attenuates H/R-triggered AC16 cell injury by promoting M2 macrophage polarization, associated with attenuated TLR4/NF-κB signaling.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2026) studied Myocardial infarction (in vitro model). Sacubitril/valsartan vs. Hypoxia/reoxygenation without Sacubitril/valsartan was evaluated on Cell viability, apoptosis, and proinflammatory cytokine production. Sacubitril/valsartan attenuated hypoxia/reoxygenation-triggered cardiomyocyte injury in vitro by promoting M2 macrophage polarization and inhibiting TLR4/NF-κB signaling.
Synapse has enriched 10 related papers. Consider them for comparative context: